Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Nov 26;6(1):bvab179. doi: 10.1210/jendso/bvab179

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 3. — A, Trend analysis of the least square estimates (LSE) of the means for fasting C-peptide showing no statistically significant difference in the changes in fasting C-peptide concentration between the ergocalciferol- and placebo-treated patients with type 1 diabetes during the 12-month trial (P = .72). B, Trend analysis of the LSEs of the means for stimulated C-peptide showing no statistically significant difference in the change in stimulated C-peptide concentration at 90 minutes between the ergocalciferol- and placebo-treated patients with type 1 diabetes during the 12-month trial (P = .31). C, LSEs of the means for glycated hemoglobin A_1c (HbA_1c) showing the change in HbA_1c between the ergocalciferol and placebo groups during the trial. Trend analysis shows an increase in HbA_1c value for the combined groups (P < .0001). There was evidence of a faster rate of increase in HbA_1c in the placebo compared to the vitamin group (P = .044). D, LSEs of the means for insulin dose–adjusted A_1c (IDAA_1c) showing the changes in IDAA_1c between the ergocalciferol and placebo groups during the trial. Trend analysis shows an increase in IDAA_1c value for the combined groups (P < .0001). Though IDAA_1c was statistically significantly lower in the placebo group at 3 months, it subsequently rose sharply when compared to the vitamin group (P = .015), suggesting that individuals in the placebo group had greater residual β-cell function at the beginning of the study but lost this function at a faster rate than individuals in the ergocalciferol group.